Lead investigator with regards to our phase 2 colorectal cancer study John L. Marshall.

John L. Marshall, MD
John L. Marshall, MD
Professor, Chief, Division of Hematology-Oncology, Department of Oncology, Georgetown University; Director, Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Hospital, Washington, DC
John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck
Serve(d) as a speaker or a member of a speakers bureau for: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck
Received research grant from: Genentech; Amgen; Taiho; Bayer; Celgene; Ipsen; Caris; Merck

There seems to be a strong relationship between him and Bayer.

Could it be he has been scanning/recruiting patients (for Bayer/cydy) already and they’ve just been waiting for the FDA green light?
(Hence NP thanking patients?)
Could it be they’ve progressed as if a partnership between Bayer/Cydy was a certainty?

I’m thinking in that direction (strongly).